GSM Treatment: Vaginal Estrogen Explained

In 1998 the FDA fast-tracked a new drug for erectile dysfunction and approved it within months. That same year, a different hormone cream, the kind that treats the female equivalent of the same problem, was just four years away from getting a warning label so severe it told women it might kill them. The warning stayed on vaginal estrogen for 27 years (14:30). The little blue pill got a red carpet. The cream got a skull and crossbones. Dr. Mary Claire Haver, a board-certified obstetrician and gynecologist and certified menopause practitioner, calls this out directly on her podcast, and the gap she describes is not really about two drugs. It is about a condition that may be the most common, cheapest, and easiest thing in midlife medicine to fix, and the one doctors fix least.

That condition now has a name almost nobody recognizes: genitourinary syndrome of menopause, or GSM. Before 2014, when a group of specialists renamed it, doctors called it atrophic vaginitis. Before that, further back, it had an even uglier label: the senile vagina (02:33). The new name is a mouthful, but Haver says it fixed something real. For the first time, the word urinary sat inside the diagnosis, because GSM is not one symptom. It is a cluster of changes in the vulva, vagina, clitoris, urethra, and bladder, all of them packed tightly into the pelvis, all of them starved of the same hormone at the same time (03:31).

Haver did not catch it in herself. She had started hormone therapy for hot flashes and assumed her whole genitourinary system was covered. What she actually had was delayed orgasm, which she blamed on stress, on aging, on anything but biology, until a friend asked a blunt question in a group chat: how much vaginal estrogen was she using? The answer was none. "I just didn't connect delayed orgasm with GSM," she says. "I had no idea" (06:16). The larger point she draws from her own blind spot: systemic hormone therapy, the pills or patches that stop hot flashes, is "a microdose compared to what your body used to make on its own," and it was never designed to fully protect the pelvis (05:26).

What Estrogen Loss Does to the Body

Haver's working analogy is a plant. Hormones are water. At puberty, estrogen and testosterone flood the genital tissue and it blossoms: the vaginal lining thickens, folds in on itself, and stays lubricated. After menopause, the water stops, and the process runs in reverse (16:22). The vaginal lining thins and flattens. The opening narrows. The labia minora, the inner folds of the vulva, slowly resorb over five, ten, twenty years, a gradual shrinking that went viral on social media after a colleague, Dr. Rachel Rubin, posted about it and sparked a comment section full of confused viewers (17:10). The clitoris, which runs mostly on testosterone rather than estrogen, shrinks too and loses blood flow and nerve sensitivity, a process with its own name: clitoral atrophy (19:53). Haver notes that testosterone decline actually starts in a woman's thirties, well before menopause, which is why delayed orgasm can show up years ahead of hot flashes.

Then there is what urologists call the ring of fire, the strip of tissue called the vestibule that surrounds the urethra, the tube that drains the bladder. It behaves more like the inside of a cheek than like vaginal tissue, and a standard speculum exam skips over it entirely, which is why so much entry pain goes undiagnosed (20:14). The bladder and urethra share a wall lined with hormone receptors, so when estrogen drops, the brain starts misreading ordinary bladder signals as emergencies: urgency, frequency, trips to the bathroom at night. In older women this chain gets dangerous. Thin, fragile tissue plus a disrupted microbiome means recurrent urinary tract infections, and in frail elderly patients a UTI can tip into sepsis, delirium, a fall, and a hip fracture, a cascade Haver says starts with an untreated genitourinary syndrome (22:40).

"Common doesn't mean normal, and it's not anyone's fault. It's biology." — Dr. Mary Claire Haver [01:20]

Why So Few Women Get Treated

The scare that built this gap dates to 2002, when headlines from the Women's Health Initiative study linked hormone therapy to breast cancer, a link Haver says was never as clear as the coverage implied (11:35). Use of systemic hormone therapy collapsed from roughly 30 to 40% of menopausal women to single digits, and the FDA slapped a sweeping boxed warning, stroke, clots, heart attack, dementia, onto every estrogen product, with no distinction between a systemic pill and a trace-dose vaginal cream (12:05). For two decades, Haver says, clinicians including herself trained and practiced in that fear. Guidelines required women to fail lubricants before hormones were even considered, despite the fact that lubricants "don't prevent a single urinary tract infection" (14:01).

The label finally changed on November 10, 2025, when the FDA removed the boxed warning from low-dose vaginal estrogen (15:20), four months after an FDA expert panel publicly called for its removal (14:30) and after what Haver describes as years of grassroots pressure, letters, and social media campaigns. "The data didn't change," she says. "The data had been there for decades" (15:20). But a label change does not retrain thousands of clinicians overnight, and the numbers show it: in a Medicare analysis, only about 7% of women diagnosed with GSM were ever prescribed vaginal estrogen (37:09), and Haver suspects actual use was lower still, since many women received the prescription and were too frightened by the old warning to fill it. A cost-savings study, with Rubin among its authors, estimated that broader use of vaginal estrogen could save Medicare between $6 billion and $22 billion a year, mostly by preventing the UTIs that lead to hospitalization in older women (38:10).

Treatment itself is almost aggressively simple. Vaginal estrogen comes as a cream, tablet, insert, or ring, and Haver's clinic favors the cream, in part because a tube costs $13 to $20 and lasts weeks (26:25). She tells patients to apply it from the first knuckle down, insert a finger halfway into the vagina, then work the rest of the cream over the clitoris, down the labia minora, and into the vestibule, the area most exams miss, twice a week.

"Treat the entire neighborhood, not just one block." — Dr. Mary Claire Haver [28:43]

Patients need about six weeks before the tissue rebuilds and symptoms ease (27:21). For pain that estrogen alone does not resolve, Haver adds vaginal DHEA, sold as Prasterone, which converts in the tissue to both estrogen and testosterone (28:43), an option she says is worth discussing with an oncologist for breast cancer survivors on aromatase inhibitors (30:00). An oral pill, ospemifene, exists for women who cannot or will not use a vaginal product, including bedbound patients in memory care whose caregivers are not trained to apply topical treatments, though it carries a small clotting risk (31:08). Lubricants and daily moisturizers still matter, Haver says, but only as comfort measures: they mask friction, they do nothing for UTIs, and "telling a patient to just relax or have a glass of wine are not treatment plans" (34:07). For muscle clenching around pain, pelvic floor physical therapy breaks the cycle that cream alone cannot touch (33:39).

What makes the whole picture frustrating, in Haver's telling, is how little stands between the current state and something much better. The treatment is already approved, already cheap, already safer by her account than aspirin or Tylenol (23:53). What is missing is a habit: doctors offering it first, and patients knowing to ask. Her proposed script is three sentences long: say you think you have genitourinary syndrome of menopause, say you want to try low-dose vaginal estrogen, and ask whether your clinician will prescribe it (43:26). If the answer is no, she says, find someone whose answer is yes.